MedKoo Cat#: 525623 | Name: Metyrapone Tartrate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Metyrapone Tartrate is an inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.

Chemical Structure

Metyrapone Tartrate
Metyrapone Tartrate
CAS#908-35-0

Theoretical Analysis

MedKoo Cat#: 525623

Name: Metyrapone Tartrate

CAS#: 908-35-0

Chemical Formula: C22H26N2O13

Exact Mass: 526.1435

Molecular Weight: 526.45

Elemental Analysis: C, 50.19; H, 4.98; N, 5.32; O, 39.51

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SU-4885; SU4885; SU 4885; Metopirone tartrate; Metyrapone tartrate
IUPAC/Chemical Name
2-methyl-1,2-di(pyridin-3-yl)propan-1-one bis((2R,3R)-2,3-dihydroxysuccinate)
InChi Key
FBSAWAHQGRDEJD-WBPXWQEISA-N
InChi Code
InChI=1S/C14H14N2O.2C4H6O6/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11;2*5-1(3(7)8)2(6)4(9)10/h3-10H,1-2H3;2*1-2,5-6H,(H,7,8)(H,9,10)/t;2*1-,2-/m.11/s1
SMILES Code
CC(C1=CC=CN=C1)(C)C(C2=CC=CN=C2)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 526.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Weiler U, Finsler S, Claus R. Influence of cortisol, gonadal steroids and an energy deficit on biochemical indicators of bone turnover in Swine. J Vet Med A Physiol Pathol Clin Med. 2003 Mar;50(2):79-87. PubMed PMID: 12667198. 2: Dickstein G, Spindel A, Shechner C, Adawi F, Gutman H. Spontaneous remission in Cushing's disease. Arch Intern Med. 1991 Jan;151(1):185-9. Review. PubMed PMID: 1985595. 3: Mito T, Shiono T, Kimura R, Tamai M. The effect of oral metyrapone on aqueous humor dynamics in normal human eyes. Acta Ophthalmol (Copenh). 1990 Oct;68(5):582-6. PubMed PMID: 2275356. 4: Galinsky RE, Corcoran GB. Suppression of acetaminophen conjugation and of conjugate elimination in the rat by metyrapone, a classical P-450 inhibitor. Drug Metab Dispos. 1988 May-Jun;16(3):348-54. PubMed PMID: 2900724. 5: Levi L, Schwartz B. Decrease of ocular pressure with oral metyrapone. A double-masked crossover trial. Arch Ophthalmol. 1987 Jun;105(6):777-81. PubMed PMID: 3034221. 6: Lye SJ, Challis JR. In vivo adrenocorticotropin (1-24)-induced accumulation of cyclic adenosine monophosphate by ovine fetal adrenal cells is inhibited by concomitant infusion of metopirone. Endocrinology. 1984 Oct;115(4):1584-7. PubMed PMID: 6207013. 7: Whipple CA, Grodzicki RL, Hourihan J, Salhanick HA. Effects of cholesterol side chain cleavage inhibitors on 11 beta-hydroxylation: linkage of mitochondrial oxygenase systems. Steroids. 1981 Jun;37(6):673-9. PubMed PMID: 6974914. 8: Nelson EB, Montes M, Goldstein M. Effectiveness of methyrapone in the treatment of acetaminophen toxicity in mice. Toxicology. 1980;17(1):73-81. PubMed PMID: 7434370. 9: Evans DM, Fox JA. Influence of Metyrapone on Development of Heterodera glycines. J Nematol. 1978 Jul;10(3):211-6. PubMed PMID: 19305843; PubMed Central PMCID: PMC2617897. 10: Patt JA Jr, Eberhart RJ. Effects of metyrapone and ACTH on intestinal absorption of immunoreactive bovine IgG in cesarean-derived pigs. Am J Vet Res. 1976 Dec;37(12):1409-13. PubMed PMID: 187090. 11: Krupin T, Mandell AI, Podos SM, Becker B. Topical corticosteroid therapy and pituitary-adrenal function. Arch Ophthalmol. 1976 Jun;94(6):919-20. PubMed PMID: 938282. 12: Carson TE, Daane TA, Weinstein RL. Long-term intramuscular administration of triamcinolone acetonide. Effect on the hypothalamic-pituitary-adrenal axis. Arch Dermatol. 1975 Dec;111(12):1585-7. PubMed PMID: 1200663. 13: Bacon GE, Larson RM, Spencer ML, Kelch RP. Intravenous metyrapone testing. Evaluation of growth hormone and adrenocorticotrophic hormone in children. Am J Dis Child. 1975 Sep;129(9):1042-4. PubMed PMID: 1190177. 14: Meikle AW, Jubiz W, West CD, Tyler FH. A simple fluorometric method for assay of plasma metyrapone. J Lab Clin Med. 1969 Sep;74(3):515-20. PubMed PMID: 5806980. 15: LEFER AM, SUTFIN DC. CARDIOVASCULAR EFFECTS OF CATECHOLAMINES IN EXPERIMENTAL ADRENAL INSUFFICIENCY. Am J Physiol. 1964 May;206:1151-5. PubMed PMID: 14208957.